Registry of patients with primary liver and biliary cancers in Central China
The Treatment and Prognosis of Primary Hepatobiliary Cancer: A Cohort Study in Central China
This study is collecting information from patients with liver and bile duct cancers in Central China to better understand their treatment and outcomes since 1998.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Tongji Hospital Academic / other |
| Locations | 1 site (Wuhan, Hubei) |
| Trial ID | NCT05520801 on ClinicalTrials.gov |
What this trial studies
This observational cohort study aims to collect and analyze clinical-pathological features of patients diagnosed with primary hepatobiliary cancer at Tongji Hospital in Wuhan. It focuses on patients who have undergone comprehensive treatment since 1998, gathering data on tumor staging, treatment modalities, and patient prognosis. The study seeks to standardize treatment approaches and provide evidence-based insights for managing hepatobiliary cancers in the region.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older diagnosed with primary liver cancer or biliary malignant tumors who have measurable lesions.
Not a fit: Patients without measurable lesions or those deemed unsuitable for the study by investigators may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment protocols and outcomes for patients with hepatobiliary cancers.
How similar studies have performed: Other studies focusing on similar cohorts and treatment standardization have shown promise, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. ≥18 years old, 2. life expectancy is at least 6 months. 3. Diagnosed as primary liver cancer or biliary malignant tumor by histopathology or confirmed by imaging as HCC (by the AASLD or guidance for the diagnosis and treatment of primary liver cancer of China (version 2022). 4. At least one measurable lesion (RECIST v1.1) 5. Subjects volunteer to participate in the study and sign informed consent. Exclusion Criteria: Patients with one or more of the following criteria should be excluded: 1. CT or MRI shows no measurable lesions (RECIST v1.1). 2. Patients after comprehensive assessment are considered by the investigators to be unsuitable for participating in the study. 3. Incomplete baseline or follow-up data 4. Suffering from more than two kinds of primary tumors
Where this trial is running
Wuhan, Hubei
- Hepatic Surgery Center, Tongji Hospital, Huazhong University of Science and Technology — Wuhan, Hubei, China (Recruiting)
Study contacts
- Principal investigator: Zeyang Ding — Tongji Hospital
- Study coordinator: Bixiang Zhang, PhD
- Email: bixiangzhang@hust.edu.cn
- Phone: 86-027-83665293
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.